Clearside Biomedical (NSDQ:CLSD) priced 6,538,462 shares of its common stock at $13.00 apiece in an $85 million underwritten public offering that’s expected to close early next week.
The Alpharetta, Ga.-based company is slated to use the funds to prepare and submit an application to the FDA for its suprachoroidal eye drug as a treatment for patients with macular edema associated with non-infectious uveitis.
Get the full story at our sister site, Drug Delivery Business News.
The post Clearside Biomedical prices $85m underwritten offering appeared first on MassDevice.
from MassDevice http://ift.tt/2oUknlC
Cap comentari:
Publica un comentari a l'entrada